1 option
Clinical review report : indication for the treatment of adult patients with diabetic macular edema who are pseudophakic. Dexamethasone (Ozurdex) (Allergan, Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Outcome assessment (Medical care)--Methodology.
- Physical Description:
- 1 online resource
- Place of Publication:
- Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2018.
- Summary:
- Dexamethasone (Ozurdex) has a Health Canada-approved indication for the treatment of macular edema following central retinal vein occlusion, the treatment of noninfectious uveitis affecting the posterior segment of the eye, and for the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic. The objective of this review is to perform a systematic review of the beneficial and harmful effects of dexamethasone 700 mcg intravitreal injection for the treatment of adults with DME who are pseudophakic.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.